ASHLEY MATTIX: Open Payments
NPI 1225647209 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,105 in 26 payments from 11 companies in 2025. Trend: 2023 $426 · 2024 $1,204 · 2025 $1,105
Food & beverage: $1,105
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $233 |
| Madrigal Pharmaceuticals | 2 | $229 |
| Janssen Biotech, Inc. | 6 | $218 |
| ABBVIE INC. | 1 | $125 |
| GENZYME CORPORATION | 2 | $64 |
| Gilead Sciences, Inc. | 3 | $57 |
| Lilly USA, LLC | 2 | $56 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 1 | $36 |
| Ardelyx, Inc. | 1 | $32 |
Products named: REZDIFFRA, TREMFYA, ENTYVIO, MAVYRET, DUPIXENT, OMVOH, XIFAXAN, VOQUEZNA.
Industry payments across AZ — which companies pay providers there.
